The Company's Board of Directors approved the
amendment of 2022 Restricted Stock Awards Issuance Rules
Date of events
2022/08/08
To which item it meets
paragraph 11
Statement
1.Date of occurrence of the event:2022/08/08
2.Date of the original announcement and reporting:2022/05/06
3.Summary of the content originally announced and reported:
The Board of Directors and the Annual Shareholders' meeting resolved the
Issuance Rules for 2022 Restricted Stock Awards Issuance Rules on
2022/05/06 and 2022/6/27 separately. Please refer to the Company's
material information announcement on the same date.
4.Reason for change and its main content:
As requested by the competent authority, the Company amended some
provisions of the 2022 Restricted Stock Awards Issuance Rules, which was
approved by the Company's Compensation Committee and Board of Directors
today.
(i)Content prior to amendment
Article 3 Qualification criteria for employees:
(1)To protect shareholder's interests, the Company shall cautiously
manage the incentive program. Only the Company's full-time
executives who are employed on the grant date and meet certain
performance requirements are eligible for this incentive plan.…
(2)The employees eligible and the number of shares granted will be
determined by the Chairman…, and then sent to Compensation Committee
and the Board of Directors for approval.
Article 8 Miscellaneous:
The Issuance Rules shall be resolved by Compensation Committee and a
majority vote in a Board of Directors meeting attended by two-thirds or
more of the directors, and then sent to the competent authority for
approval.…
(ii)Content after amendment
Article 3 Qualification criteria for employees:
(1)To protect shareholder's interests, the Company shall cautiously
manage the incentive program. Only the Company's full-time
executives who are employed on the grant date and meet certain
performance requirements are eligible for this incentive plan.…
The above-mentioned executives are limited to CEO and Senior Vice
President.…
(2)The employees eligible and the number of shares granted will be
determined by the Chairman…, and then sent to Compensation
Committee and the Board of Directors for approval. Only for
managerial employees or directors who are also employees, approval
by the Compensation Committee must be obtained first.
Article 8 Miscellaneous:
The Issuance Rules shall be resolved by Compensation Committee and a
majority vote in a Board of Directors meeting attended by two-thirds
or more of the directors, and then sent to the competent authority for
approval. The same shall apply for revisions after issuance.
5.Impact on the Company's finance and business after the change:None
6.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
OBI Pharma Inc. published this content on 08 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 08 August 2022 08:43:08 UTC.
OBI Pharma, Inc. is a Taiwan-based company principally engaged in the development of new pharmaceuticals. The Company mainly operates its businesses through the research and development of novel cancer and infectious disease therapies. It also develops next generation active immunotherapies to treat cancers, including lung, prostate, pancreatic, stomach and ovarian cancers. It is engaged in the development of OBI-822 (formerly OPT-822/821), an active immunotherapy new drug for metastatic breast cancer; the research and development of therapeutic vaccine OBI-833 for the treatment of new generation of cancers, as well as the development of cancer testing reagent OBI-868.
OBI PHARMA, INC. 
